Establishing the optimal dose of nitric oxide in acute vasoreactivity testing in patients with pulmonary hypertension with use of the Bronchial Control Treatment System (RCD code: II)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 4
Abstract
The key point in the diagnostic algorithm for pulmonary hypertension plays the pulmonary reactivity testing, the agent most frequently used in the test is inhaled nitric oxide (iNO). Various dosages of iNO were used in acute vasoreactivity testing so far, so we aimed to determine the most effective dose of iNO administered in the acute vasoreactivity testing. Ten consecutive patients was enrolled to the open label study. To assess the most effective dose of iNO increasing concentrations of iNO: 10 ppm, 20 ppm and 30 ppm were administered. In the study statistically significant reduction in mean pulmonary artery pressure after each dose of iNO as compared to baseline was found. There were no significant differences in mean pulmonary artery pressure between subsequent iNO doses (10 ppm vs. 20 ppm, 20 ppm vs. 30 ppm). Statistically significant reduction of systolic pulmonary artery pressure after iNO at the dose of 20 ppm as compared to a dose of 10 ppm was observed. No significant side effects during iNO administration were observed. We concluded that the dose of inhaled nitric oxide used in the acute vasoreactivity testing should not exceed 20 ppm, it is effective and safe dose.
Authors and Affiliations
Magdalena Kaznica-Wiatr, Maria Olszowska, Piotr Podolec
Keywords
Related Articles
- EP ID EP242019
- DOI 10.20418/jrcd.vol2no4.189
- Views 131
- Downloads 0
Spontaneous pneumothorax
Pneumothorax is defined as the occurrence of air in the pleural space. From a clinical standpoint, pneumothorax can be classified as spontaneous (without an obvious triggering factor) or nonspontaneous. Primary spontaneo...
Journal of Rare Cardiovascular Diseases: Moving towards maturity, and implementing the Krakow RCD Classification as a milestone
Dear Readers – our Friends and Colleagues,The present, third, issues of your quarterly Journal of Rare Cardiovascular Diseases is an important landmark in the life of the Journal; the life that presents a process from in...
Plasma Endothelin‐1 in patients with atrial septal defect – the novel diagnostic indicator (RCD code: IV-2B.1)
Background: The study aimed to assess the level of plasma Endothelin-1 (ET-1) in patients before and after transcatheter closure of atrial septal defect (ASD) and to evaluate the usefulness of measuring ET-1 levels for...
A 23‑year‑old woman with Marfan syndrome and spine deformity (RCD code: I-2A.1)
Marfan syndrome is one of the most common heritable connective tissue disorders that is caused by various mutations of the Fibrillin-1(FBN1) gene. The cardinal features of Marfan syndrome are aortic root dilatation and e...
“There is no failure except no longer trying” Elbert Hubbard
The way of time fly is inevitable and the end of 2015 is slowly approaching. Not long ago we were celebrating its onset but now it is time for a farewell. This time of the year is just perfect for a few reflections. Firs...